Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

NCT06649721 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Drug-resistant Tuberculosis
Pulmonary Tuberculosis
Rifampin-resistant Tuberculosis

Interventions

DRUG: bedaquiline
DRUG: delamanid
DRUG: linezolid
DRUG: Levofloxacin
DRUG: Clofazimine

Sponsor

Huashan Hospital

Collaborators

[object Object]